Pacira BioSciences (PCRX) Non Operating Income (2010 - 2026)

Pacira BioSciences' Non Operating Income history runs 17 years deep, the most recent figure standing at -$1.9 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 128.35% year-over-year to -$1.9 million in Q1 2026; TTM through Mar 2026 was -$10.9 million, a 166.07% decrease from a year earlier, with the FY2025 full-year figure at -$2.3 million, down 122.57% from the prior year.
• Non Operating Income declined to -$1.9 million in Q1 2026 per PCRX's latest filing, from -$1.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at $8.3 million in Q2 2024 and bottomed at -$23.4 million in Q1 2023.
• The 5-year median for Non Operating Income is -$1.8 million (2025), against an average of -$3.9 million.
• Biggest YoY gain for Non Operating Income was 1469.16% in 2025; the steepest drop was 315.21% in 2025.
• Year by year, Non Operating Income stood at -$8.2 million in 2022, then surged by 106.75% to $552000.0 in 2023, then surged by 48.91% to $822000.0 in 2024, then plunged by 315.21% to -$1.8 million in 2025, then dropped by 7.63% to -$1.9 million in 2026.
• Per Business Quant, the three latest PCRX Non Operating Income figures stand at -$1.9 million (Q1 2026), -$1.8 million (Q4 2025), and $3.2 million (Q3 2025).